Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes inadequately controlled with metformin monotherapy: VERTIS-Asia

被引：0

作者：

Yang, M. ^{[1
]}

Ji, L. ^{[2
]}

Liu, Y. ^{[3
]}

Miao, H. ^{[4
]}

Xie, Y. ^{[5
]}

Wang, W. ^{[1
]}

Mu, Y. ^{[1
]}

Yan, P. ^{[1
,6
]}

Pan, S.

Lauring, B. ^{[7
]}

Liu, S. ^{[8
]}

Huyck, S. ^{[7
]}

Wang, D. ^{[8
]}

Terra, S. G. ^{[9
]}

机构：

[1] Pfizer China R&D Co, Shanghai, Peoples R China

[2] Peking Univ, Peoples Hosp, Beijing, Peoples R China

[3] Yancheng First Peoples Hosp, Yancheng, Peoples R China

[4] Nanjing Med Univ, Affiliated Hosp 2, Nanjing, Jiangsu, Peoples R China

[5] Pingxiang Peoples Hosp, Pingxiang, Peoples R China

[6] Pfizer Inc, New York, NY USA

[7] Merck & Co Inc, Kenilworth, NJ USA

[8] Merck & Co Inc, Beijing, Peoples R China

[9] Pfizer Inc, Andover, MA USA

来源：

DIABETOLOGIA | 2018年 / 61卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

633

引用

页码：S307 / S308

页数：2

共 50 条

[21] Efficacy and Tolerability of Vildagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy
Goodman, M.
Thurston, H.
Penman, J.
[J]. HORMONE AND METABOLIC RESEARCH, 2009, 41 (05) : 368 - 373
[22] Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled type 2 diabetes despite diet and exercise: the 52-week VERTIS MONO study
Terra, S.
Frias, J.
Goldman, A.
Aronson, R.
Darekar, A.
Huyck, S.
Lauring, B.
[J]. DIABETOLOGIA, 2017, 60 : S408 - S408
[23] Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin
Hollander, Priscilla
Hill, Julie
Johnson, Jeremy
Jiang, Zhi Wei
Golm, Gregory
Huyck, Susan
Terra, Steven G.
Mancuso, James P.
Engel, Samuel S.
Lauring, Brett
Liu, Jie
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (08) : 1335 - 1343
[24] Long-Term Efficacy and Safety of Ertugliflozin in Patients (Pts) with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled with Metformin (MET) Monotherapy-104-Week VERTIS MET Trial
Gallo, Silvina
Charbonnel, Bernard
Goldman, Allison
Shi, Harry
Huyck, Susan
Darekar, Amanda
Lauring, Brett
Terra, Steven
[J]. DIABETES, 2018, 67
[25] The Efficacy and Safety of Imeglimin as Add-On Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
Fouqueray, Pascale
Pirags, Valdis
Inzucchi, Silvio
Bailey, Clifford J.
Schernthaner, Guntram
Diamant, Michaela
Lebovitz, Harold E.
[J]. DIABETES, 2012, 61 : A257 - A257
[26] SAFETY AND EFFICACY OF SITAGLIPTIN COMPARED WITH GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED WITH METFORMIN MONOTHERAPY
Abrar, Amjad
Khan, Shimal
Rehman, Mehboob Ur
Jan, Tehmina
Faisal, Muhammad
[J]. GOMAL JOURNAL OF MEDICAL SCIENCES, 2013, 11 (01): : 3 - 7
[27] The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
Fouqueray, Pascale
Pirags, Valdis
Inzucchi, Silvio E.
Bailey, Clifford J.
Schernthaner, Guntram
Diamant, Michaela
Lebovitz, Harold E.
[J]. DIABETES CARE, 2013, 36 (03) : 565 - 568
[28] Efficacy and safety of acarbose in patients with type 2 diabetes inadequately controlled with metformin
Magner, J
Taylor, T
Krol, A
Rosenstock, J
[J]. DIABETOLOGIA, 1998, 41 : A231 - A231
[29] Efficacy and safety of acarbose in patients with type 2 diabetes inadequately controlled with metformin
Rosenstock, J
Magner, J
Krol, A
Taylor, T
[J]. DIABETES, 1998, 47 : A351 - A351
[30] Efficacy and safety of saxagliptin plus metformin versus acarbose plus metformin in type 2 diabetes patients inadequately controlled with metformin monotherapy
Du, J.
Liang, L.
Fang, H.
Xu, F.
Li, W.
Shen, L.
Mu, Y.
[J]. DIABETOLOGIA, 2016, 59 : S372 - S372

← 1 2 3 4 5 →